← Human Trials & Peer-Reviewed Studies
Effect of 1-year oral cholecalciferol on a metabolic profile and blood pressure in poor-controlled type 2 diabetes mellitus: an open-label randomized controlled pilot study.
Plain-language guide to PMID 32804345 (2021): open-label randomized controlled trial of Vitamin D, K2, Magnesium and Zinc in 2 patients, low blood pressure and orthostatic hypotension.
Key Facts
- PMID
- 32804345
- Journal
- Journal of endocrinological investigation
- Year
- 2021
- Study type
- Randomized Controlled Trial
- Authors
- Barale M et al. (4 authors)
- DOI
- 10.1007/s40618-020-01373-8
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc in the context of low blood pressure and orthostatic hypotension.
Who Took Part
According to the abstract, 2 patients were involved.
The age groups tagged for this paper are older adults, both men and women.
How the Study Was Run
The researchers set it up as a randomized, open-label and pilot study.
Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.
Being open-label, the Vitamin D, K2, Magnesium and Zinc study did not mask who received what.
It is described as a pilot, a small early test of whether a larger Vitamin D, K2, Magnesium and Zinc study would be practical.
Changes in parameters of glucose, lipid and blood pressure control at 3, 6, 9 and 12 months vs. baseline were assessed.
What Was Measured
PubMed files the paper under topics including Blood Pressure, Body Mass Index, Calcium-Regulating Hormones and Agents, Cholecalciferol, Cholesterol, HDL, Diabetes Mellitus, Type 2 and Glycated Hemoglobin.
The authors tagged it with the keywords Body composition, Dyslypidemia, Hypertension, Type 2 diabetes mellitus and Vitamin D deficiency.
What This Means in Plain Language
The paper is a randomized, open-label and pilot study of Vitamin D, K2, Magnesium and Zinc in 2 patients in people with low blood pressure and orthostatic hypotension.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2021 (Journal of endocrinological investigation), a journal based in Italy.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, Low blood pressure and orthostatic hypotension research.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
- Low blood pressure and orthostatic hypotension research
- Vitamin D, K2, Magnesium and Zinc in the library
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.